Enlarge (credit: jridgewayphotography)
When Mylan’s CEO, Heather Bresch, appeared before lawmakers last September to explain the skyscraping price of life-saving EpiPens, she touted coupons that would cut out-of-pocket costs for customers rather than plans to lower prices.

Executives for Turing Pharmaceuticals, Valeant, Marathon, Kaléo, and many others used the same strategy amid price-gouging claims.
But the wallet-friendly deals are deceptive, lawmakers and advocates argue.

They recommend a hard pass—and a growing number is working on legislation to help you do it.
After an initial approval last week, a California bill heading to the Senate aims to prohibit drug companies from offering coupons for brand-name drugs if a cheap generic is available, the Los Angeles Times reports.
Similar legislation is pending in New Jersey and passed some five years ago in Massachusetts.
Read 7 remaining paragraphs

Leave a Reply